Monsanto is weighing whether to launch another attempt to take over Swiss agrochemicals giant Syngenta, after the Swiss company snubbed an offer from a Chinese group, the Bloomberg financial news agency reported on Wednesday.
Syngenta turned down a $47-billion bid from Monsanto in August and has reportedly backed away from a $41.6-billion offer from China National Chemical (ChemChina).
Syngenta and ChemChina were said to still be in talks, but Monsanto’s chief operating officer Brett Begemann told reporters that the failure of those two sides to strike a deal had spurred Monsanto to rethink another offer.
“If you are asking me are we having conversations inside of Monsanto, well of course we are,” Bloomberg quoted Begemann as saying.
Source: The Local Switzerland
This equipment will significantly lower the site’s CO2 emissions, reduce flaring and save around 60 gigawatt hours (GWh) energy each year. Project kick-off is in February 2021, with completion planned for 2023.
The acquisition significantly strengthens and expands Grace’s existing pharma portfolio. Pharma & Consumer is the largest, fastest growing and most profitable subsegment within Grace’s Materials Technologies business.
Solvay says it has decided to organize its soda ash and derivatives business into a separate and fully controlled legal structure.
